找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drugs for the Treatment of Parkinson’s Disease; Donald B. Calne (Head) Book 1989 Springer-Verlag Berlin Heidelberg 1989 Parkinson.adverse

[復(fù)制鏈接]
樓主: charity
21#
發(fā)表于 2025-3-25 03:49:35 | 只看該作者
22#
發(fā)表于 2025-3-25 07:28:36 | 只看該作者
,Clinical Actions of ,-Deprenyl in Parkinson’s Disease,ess of Parkinson’s disease. In this chapter, the clinical experience to date of the use of .-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.
23#
發(fā)表于 2025-3-25 14:02:45 | 只看該作者
Mohamed Riduan Abid,Driss Benhaddouand postsynaptic elements. Other neurotransmitter abnormalities, however, have been observed in this and other basal ganglia diseases. This chapter will focus on the normal distribution of neurotransmitter receptors in human basal ganglia and the receptor abnormalities observed in Parkinson’s disease.
24#
發(fā)表于 2025-3-25 17:32:15 | 只看該作者
Worship Spaces: 1001–2000 Seatsty of deficits (such as dementia), and experience with problematic adverse reactions (such as fluctuations in response). Besides making reliable sensitive assessment more important, complications such as dementia and fluctuations in response make the process of evaluation more difficult.
25#
發(fā)表于 2025-3-25 23:13:43 | 只看該作者
Benjamin Schwessinger,John P. Rathjenerature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (. et al. 1980).
26#
發(fā)表于 2025-3-26 03:58:46 | 只看該作者
27#
發(fā)表于 2025-3-26 06:30:54 | 只看該作者
28#
發(fā)表于 2025-3-26 09:53:46 | 只看該作者
,Lisuride Pharmacology and Treatment of Parkinson’s Disease,erature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (. et al. 1980).
29#
發(fā)表于 2025-3-26 15:39:17 | 只看該作者
Developmental and Social Prevention, this chapter we will review anticholinergic and amantadine treatment of Parkinson’s disease, emphasizing the proposed mechanisms of action, what is known of the pharmacokinetics, the clinical effectiveness and side effects.
30#
發(fā)表于 2025-3-26 16:49:56 | 只看該作者
,Anticholinergic Drugs and Amantadine in the Treatment of Parkinson’s Disease, this chapter we will review anticholinergic and amantadine treatment of Parkinson’s disease, emphasizing the proposed mechanisms of action, what is known of the pharmacokinetics, the clinical effectiveness and side effects.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-2-6 15:47
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
怀化市| 乐业县| 建阳市| 西丰县| 三原县| 东辽县| 高雄县| 广宗县| 宾川县| 新平| 南阳市| 庐江县| 久治县| 南江县| 海盐县| 奇台县| 红原县| 行唐县| 平度市| 宣武区| 肥城市| 同德县| 上犹县| 思茅市| 辽阳市| 宝丰县| 芒康县| 呼和浩特市| 延吉市| 自贡市| 怀仁县| 开封县| 武冈市| 仁寿县| 平安县| 灵石县| 扎鲁特旗| 鸡泽县| 津南区| 交城县| 常熟市|